Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Refractory Erythema Multiforme
NCT05875714Phase 2Completed
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apremilast in erythema multiforme (EM). Started Jan 2022; status: completed.
02
Drugs
apremilast
03
Conditions
erythema multiforme (EM)
Beyond the preview
Go deeper on NCT05875714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875714.